Objective To assess the reliability and validity of the Chinese version of Prodromal Questionnaire-Brief Version (PQ-B).Methods By convenience sampling,122 college students and clinical psychology outpatients were assessed by PQ-B and Symptom Checklist 90 (SCL-90).Eighty among them were rctcstcd with the PQ-B after 2 weeks to test test-retest reliability.Correlation analysis,exploratory factor analysis were used for data processing.Results The internal consistency reliability of the Chinese version of PQ-B was 0.894,the correlation coefficient between each item and total score were higher than 0.347 (all P ＜ 0.01),and when each of the total items deleted,the Cronbach' s Alpha of the whole score was lower than 0.894.Moreover,the test-retest reliability was 0.71 (P ＜ 0.01) and the Guttman Split-Half Coefficient was 0.874.The exploratory factor analysis showed that KMO was 0.833,and 65.22％ of the total variation could be explained by 6 factors,and the rotated pattern matrix value of item were 0.404-0.896 by direct oblimin.The total PQ-B score and the score of most of the extracted factors was significantly correlated with SCL-90(r=0.233-0.725,P＜0.01),while factor 5 had low correlation with subscales of Obsessive-Compulsive,Interpersonal Sensitivity,Depression and Hostility in SCL-90(r=0.154-0.206,P＞0.01).Conclusion The Chinese version of PQ-B suggested primarily good reliability and validity.

This study is to investigate the effect of downregulation histone deacetylases 1 (HDAC1) gene by the technology of RNA interference on the differentiation of HL-60 cells line. The optimal segment targeting HDAC1 gene was designed and transfected into HL-60 cells by Lipofectamine 2000. The HDAC1 mRNA and protein level were detected by RT-PCR and Western blotting. The morphologic change of HL-60 cells was detected by an optical microscope with Wright-Giemsa. Cell differentiation was tested by NBT reduction assay. Expression of CD13, CD33 and CD14 was measured by flow cytometry. The results indicated that HDAC1 mRNA and protein were markedly suppressed by the siRNA targeting HDAC1 in a concentration-dependent manner. HDAC1 siRNA promoted cell differentiation. HL-60 cells became more mature in morphology after transfected to HDAC1 siRNA at a concentration of 30-60 nmol x L(-1) for 24 h. NBT reduction ability of HDAC1 siRNA with 30 nmol x L(-1) was 0.31 +/- 0.09, compared with negative control (0.20 +/- 0.02) (t = -3.1, P < 0.01), and with 60 nmol x L(-1) was 0.25 +/- 0.02 in comparison with negative control (0.21 +/- 0.04) (t = -2.12, P < 0.05). But it has no change in HDAC1 siRNA > or = 120 nmol x L(-1). After transfection with 60 nmol x L(-1) HDAC1 siRNA to HL-60 cells, the expression of CD13 was (96.50 +/- 0.70)% in compared to siRNA-NC (3.39 +/- 0.68) % (t = 164.9, P < 0.000 5), CD33 was (66.73 +/- 0.50) % in compared to siRNA-NC (96.80 +/- 1.70) % (t = 43.4, P < 0.000 5). CD14 was (0.53 +/- 0.00) % by comparison with siRNA-NC (0.49 +/- 0.02) % (t = -0.97, P > 0.1). HDAC1 siRNA promoted cell differentiation in indicated concentration. HDAC1 might be one of the targets of gene therapy for leukemia.

The research progresses of iron homeostasis and the diagnosis of hereditary iron overload in the 56th American Society of Hematology (ASH) annual meetings were reviewed.Over the last 2 decades,the discovery of mutations in genes leading to hereditary disorders of iron overload,iron deficiency,and iron maldistribution had accelerated our understanding of human iron homeostasis.This article provided an updated overview of the human iron cycle,regulation of iron homeostasis,how perturbations in these homeostatic mechanisms led to iron overload disease and strategies for the diagnosis of hereditary iron overload.

Progress of guidelines for quantifying iron overload in the 56th American Society of Hematology (ASH) annual meetings was reviewed.This article reviewed the use of historical data,serological measures,and MRI to estimate somatic iron burden.Before chelation therapy utilization,transfusional volume was an accurate method for estimating liver iron burden,whereas transferrin saturation reflected the risk of extrahepatic iron deposition.Liver biopsy was invasive and plagued by sampling variability.In the current study,we recommended annual liver iron concentration to be measured by MRI for all patients on chronic transfusion therapy.And it was important to measure cardiac T2* by MRI every 6-24 months depending on the clinical risk of cardiac iron deposition.Recent validation data for pancreas and pituitary iron assessments was also presented,while the further confirmatory data was suggested before these techniques could be recommended for routine clinical use.

New progresses of timing of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS) and aplastic anemia in the 56th ASH annual meetings were reviewed.Allo-HSCT for MDS was a potentially curative procedure,but it was associated with a significant risk of morbidity and mortality.With the recent approval of disease-modifying agents,the appropriate timing of alloHSCT needed to be addressed.For low and intermediate-1 IPSS risk groups,the decision to delay HSCT from the time of diagnosis maximized overall survival.For patients with intermediate-2 and high-risk disease,immediate HSCT at the time of diagnosis was associated with a greater number of life-years than HSCT at a delayed time point.The methods that underwent HSCT were after azacitidine,leukemia-type induction chemotherapy,or both.for severe aplastic anemia (SAA),HSCT was a proven cure,but HLA-matched sibling donors were found in fewer than 25 ％ of newly diagnosed patients.The use of early unrelated donor HSCT was an evolving concept that will became more accepted as improvements in HSCT outcomes continued.Moving forward,HLA-matched related and unrelated donor HSCT will likely become the treatment of choice for most patients with higher-risk MDS and newly diagnosed SAA.

New progress of guidelines for novel targets to iron overload in the 56th American Society of Hematology (ASH) annual meeting was reviewed.β-thalassemia and hereditary hemochromatosis disorders,and inappropriately low levels of the liver hormone hepcidin are responsible for the increased iron absorption,leading to toxic iron accumulation in many organs.Several studies have shown that targeting iron absorption could be beneficial to reducing or preventing iron overload in these 2 disorders.New approaches target Tmprss6.Additional strategies in β-thalassemia are showing beneficial effects in ameliorating ineffective erythropoiesis and anemia.The goal of this review is to discuss the major factors controlling iron metabolism and erythropoiesis and to discuss potential novel therapeutic approaches to reduce or prevent iron overload in these 2 disorders and ameliorate anemia in β-thalassemia.

BACKGROUND:Bioceramic has similar components compared to human bone tissue and it has shown good ostoconductivity both in vitro and in vivo.Meanwhile,it is biocompatible.So,bioceramics is considered as one of the most promising materials which can be applied to bone tissue engineering.OBJECTIVE:To summarize the properties of bioceramics and the research progress in experimental studies and clinical applications.METHODS:PubMed was searched for relevant articles published during 2000 to 2016 with the key words of bioceramics,hydroxylapatite,calcium phosphate,bioglass,bone tissue engineering in English.RESULTS AND CONCLUSION:Bioceramic materials can be divided into two categories:calcium phosphates and bioactive glass.Calcium phosphates have good biocompatibility and osteoconductivity,while the mechanical property is not so satisfying.Bioactive glass is biocompatible and beneficial to the expression of some osteogenic genes,but it is brittle and weak.Some kinds of bioceramics have already been applied to clinical practice.In recent years,calcium phosphates have also been used as coated materials to improve the properties of tissue-engineered scaffolds.Bioceramics combined with synthetic polymers,shows better mechanical performance and biodegradation.Even so,it still has plenty of problems and challenges as a widely used bone repair material in clinical practice.

New progress of guidelines for established and novel agents for myelodysplastic syndromes (MDS) in the 56th American Society of Hematology (ASH) annual meetings was reviewed.MDS was the most commonly diagnosed myeloid malignancy.According to prognostic scoring systems,the MDS patients were divided into lower-risk and higher-risk group.The goal of treatment for lower-risk patients is transfusions minimization and life quality optimization,while the goal of treatment for higher-risk patients is transformation to acute leukemia delay and life prolongation.The lower-risk patients with isolated cytopenia are treated with erythropoiesis-stimulating agents or growth factors.For patients with the del (5q) cytogenetic abnormality or those who were failure in these initial treatment,lenalidomide or experimental agents may be administrated.Lower-risk patients with multiple cytopenia may be treated with immunosuppressive drugs or low-dose hypomethylating agents.For patients with higher-risk disease,hypomethylating agents are the preferred initial treatment approach,with evaluation for hematopoietic cell transplantation at diagnosis.

Objective To intelligently adjust the driving force of a remote-controlled drug delivery capsule based on the postural information in intestines,so as to achieve the control of speed and dosage of drug delivery and reduce the energy consuming.Methods A six-axis sensor MPU6050 was used,and its Z axis was coincident with the central axis of the drug delivery capsule so as to made the medicine discharge port pointing to the Z direction.The angular velocities and accelerations of X,Y,Z axes were monitored,transformed to quaternion with built-in digital motion processor,and then converted to Euler angle form.The intelligence adjustment of driving force could be achieved by accessing the real-time attitude angle of the capsule.Results The results of experiments showed that the error between the actual and the attitude angle measured by the sensor was less 1°.Conclusions The intelligent adjustment scheme of driving force of a gastrointestinal remote-controlled drug delivery capsule was designed.The real-time attitude angles of the capsule could be obtained with high spped and precision.This study can provide the theoretical and experimental basis for the intelligent adjustment of the driving force.

The integrated management and re mote application of dynamic ECG data is the future of the Holter System. This ar ticle introduces a kind of Dynamic ECG Review & Analysis Workstation that includ es the function of integrated management and network. It has solved well the problems of common usage, archiving, total ECG analysis and remote transmission which exist in the traditional ECG Review & Analysis Systems.